Most pharmacovigilance platform evaluations focus on case-level capability can it validate against E2B(R3), can it code accurately. Those questions matter, but they miss a dimension that becomes critical the moment an organization is running more than one study at a time: whether safety signals, case patterns, and compliance status are visible across the full study portfolio, or trapped in per-study silos that require manual compilation to see clearly. Here's a practical framework for assessing a platform on the three dimensions that actually separate strong PV programs from adequate ones — cross-study visibility, faster adverse event reporting, and inspection-ready compliance.
Ask whether a case pattern in one study is visible against the same drug or population in another. A safety signal that appears isolated within a single study can look very different once compared against similar cases in a related study for the same product. Platforms that only report at the individual study level miss this pattern entirely unless someone manually cross-references.
Ask how quickly a portfolio-level safety question can be answered. "How many cases of this event type have we seen across all active studies this quarter" should be answerable in minutes, not require compiling exports from each study separately.
Ask whether case quality and completeness trends are visible across the safety program, not just per study. A reviewer whose case quality is consistently lower than average is easier to identify and support when that pattern is visible across their full caseload, not buried within individual study reports.
Ask what happens between an event occurring and the clock starting on expedited reporting obligations. The gap between event occurrence and case creation directly affects how much of the regulatory reporting window remains once the formal process actually begins.
Ask how validation and quality scoring affect time to submission. Real-time field-level validation that catches issues at entry, rather than during a separate review pass afterward, directly shortens the path from case creation to a submission-ready report.
Ask whether coding speed depends on individual reviewer familiarity or a shared, database-grounded reference. Coding that pulls from an actual MedDRA hierarchy and historical precedent is both faster and more consistent than coding that depends entirely on individual reviewer recall.
Ask whether the audit trail explains reasoning, not just logs actions. An inspector reviewing case handling wants to understand why a decision was made, not just that an action occurred at a certain timestamp.
Ask how the platform demonstrates consistency across reviewers and time. A single well-documented case doesn't demonstrate a defensible process — consistency across the full caseload, over the full study duration, does.
Ask what happens when a case is queried or rejected. Whether the platform surfaces recurring root causes across similar queries, rather than treating each one as an isolated fix, indicates whether systemic issues get caught early or repeat indefinitely.
| Dimension | Weak Signal | Strong Signal |
|---|---|---|
| Cross-study visibility | Reports built per study only | Portfolio-level patterns visible directly |
| Cross-study visibility | Manual compilation needed for portfolio questions | Answerable in minutes |
| Faster AE reporting | Manual case creation lag | Minimal gap between event and case creation |
| Faster AE reporting | Validation only before final submission | Real-time, field-level validation at entry |
| Inspection readiness | Audit trail logs actions only | Audit trail captures reasoning and confidence |
| Inspection readiness | Each query fixed in isolation | Recurring root causes surfaced across cases |
Regulatory expectations for pharmacovigilance extend beyond individual case handling to the consistency and defensibility of the safety program as a whole. An inspector examining a multi-study safety program is likely to ask about cross-study patterns and program-level consistency, not just whether individual cases were each handled correctly in isolation.
AI VigiCheck applies consistent, real-time E2B(R3) validation and case quality scoring across every study on the platform, supporting the kind of portfolio-wide consistency that's difficult to achieve with per-study processes. Because case data lives on a connected platform rather than siloed per study, cross-study pattern visibility is a structural property of the system rather than a manual compilation exercise. The Medical Coding Assistant's database-grounded coding and historical fallback support both speed and consistency across the full safety program.
Evaluating a pharmacovigilance platform on case-level capability alone misses the dimension that matters most once an organization runs more than one study whether the platform can show a defensible, consistent picture across the entire safety program, not just within each individual study in isolation.
See how Cloudbyz's PV platform supports cross-study visibility and inspection readiness book a demo with Cloudbyz.